Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its interim results for the half year ended 30 September 2016 on Monday 5 December 2016.
A meeting for analysts will be held at 11.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.